Our mission

The RECIST Working Group (RWG) was established in 1995 to review the objective response criteria in use at the time and to explore the utility of the use of unidimensional measurements in response assessment, as proposed by CCTG. The initial working group was led by academic members of the EORTC, CCTG and NCI (USA), with a database being created and maintained under the governance of the EORTC. Over the years, the membership of the Working Group was expanded to include other interested or expert members, including some representation from the pharmaceutical industry, as original members joined pharma, or expertise was identified. RECIST v1 was successfully implemented in 2000, and an update (RECIST 1.1) was released in 2009.


Further updates to RECIST are currently under investigation, including functional imaging, and validation of RECIST for non-cytotoxic therapeutics. The RECIST working group has forged new liaisons with other groups/organisations involved in related initiatives such as imaging technology and database creation. The  warehouse has been updated with numerous trials of targeted agents (including 10,000 patients), and analyses are just starting. In addition to these initiatives described above, we will create a warehouse of clinical trials testing immune checkpoint inhibitors to allow the validation of current and future criteria to evaluate efficacy. We will also explore the role of RECIST  in evaluating response of brain metastases.